Inclusion Criteria:

- ≥ 16 years of age at the time of obtaining informed consent

- Eastern Cooperative Oncology Group performance status of 0 or 1 at screening

- At least one PET-avid measurable lesion according to Modified Lugano Criteria after
the last line of therapy.

- Confirmed histological diagnosis of active relapse/refractory cHL

- Failed at least 2 prior lines of systemic therapy.

- No previous treatment with anti-TIM-3.

- Adequate organ and bone marrow function

- Non-pregnant women and willingness of female patients to avoid pregnancy or male
participants willing to avoid fathering children through highly effective methods of
contraception

- Minimum body weight ≥ 40 kg for all participants.

Exclusion Criteria:

- Unresolved toxicities of ≥ Grade 2 from prior therapy

- Any prior ≥ Grade 3 imAE while receiving prior checkpoint inhibitor immunotherapy

- Patients with CNS involvement or leptomeningeal disease.

- History of organ transplantation (e.g., stem cell or solid organ transplant).

- Any venous or arterial thromboembolic event within ≤ 6 months prior to the first dose
of study intervention.

- Active infection including TB, HIV, hepatitis A, chronic or active hepatitis B,
chronic or active hepatitis C, active COVID-19 infection

- History of arrhythmia which is requires treatment, symptomatic or uncontrolled atrial
fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia

- Uncontrolled intercurrent illness.

- Active or prior documented pathologically confirmed autoimmune or inflammatory
disorders.

- Past medical history of interstitial lung disease (ILD), drug-induced ILD, radiation
pneumonitis requiring steroid treatment, or any evidence of clinically active ILD

- Other invasive malignancy within 2 years prior to screening

- Congenital long QT syndrome or history of QT prolongation associated with other
medications that cannot be changed or discontinued based on a cardiologist assessment

- Current or prior use of immunosuppressive medication within 14 days prior to the first
dose of study intervention

- Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal
therapy for cancer treatment.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Eligibility last updated 11/22/23. Questions regarding updates should be directed to the study team contact.